Pneumolysin-mediated activation of NFκB in human neutrophils is antagonized by docosahexaenoic acid

Clinical and Experimental Immunology

Volumn 140, Issue 2, 2005, Pages 274-281

  Fickl, H ^a   Cockeran, R ^a   Steel, H C ^a   Feldman, C ^b   Cowan, G ^c   Mitchell, T J ^c   Anderson, R ^a,d  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Department of Immunology ^*  (South Africa)

Author keywords

Calcium; Docosahexaenoic acid; Neutrophils; Nuclear factor kappa B (NF B); Pneumolysin

Indexed keywords

BACTERIAL TOXIN; CALCIUM CHELATING AGENT; CALCIUM ION; DOCOSAHEXAENOIC ACID; EGTAZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OMEGA 3 FATTY ACID; PNEUMOLYSIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; RADIOASSAY; RADIOMETRY;

ADULT; BACTERIAL PROTEINS; CALCIUM; CELLS, CULTURED; DOCOSAHEXAENOIC ACIDS; HEMOLYSIS; HUMANS; INTERLEUKIN-8; NEUTROPHIL ACTIVATION; NEUTROPHILS; NF-KAPPA B; RECOMBINANT PROTEINS; STREPTOLYSINS;

EID: 17644428099     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02757.x     Document Type: Article

References (46)

1. Cockeran R, Theron AJ, Steel HC et al. Proinflammatory interactions of pneumolysin with human neutrophils. J Infect Dis 2001; 183:604-11.
2. Cockeran R, Durandt C, Feldman C, Mitchell TJ, Anderson R. Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils. J Infect Dis 2002; 186:562-5.
3. Strickland I, Kisich H, Hauk PJ et al. High constitutive glucocorticoid receptor β in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 2001; 193:585-93.
4. Jounblat R, Kadioglu A, Mitchell TJ, Andrew PW. Pneumococcal behaviour and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect Immun 2003; 71:1813-9.
5. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001; 183:827-30.
6. Cockeran R, Anderson R, Feldman C. Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease. Expert Rev Anti-Infect Ther 2003; 1:231-9.
7. García-Suárez MM, Cabal-Cima MD, Florez N et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004; 72:4534-40.
8. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune disease. J Am Coll Nutr 2002; 21:495-505.
9. Gadek JE, DeMichele SJ, Karlstad MD et al. Effect of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med 1999; 27:1409-20.
10. Grimminger F, Mayer K, Kiss L, Wahn H, Walmrath D, Seeger W. Synthesis of 4- and 5-series leukotrienes in the lung microvasculature challenged with Escherichia coli hemolysin: critical dependence on exogenous free fatty acid supply. Am J Respir Cell Mol Biol 1997; 16:317-24.
11. Rose F, Kiss L, Grimminger F et al. E. coli hemolysin-induced lipid mediator metabolism in alveolar macrophages: impact of eicosapentaenoic acid. Am J Physiol 2000; 279:L100-9.
12. Cockeran R, Theron AJ, Feldman C, Mitchell TJ, Anderson R. Docosahexaenoic acid and eicosapentaenoic acid antagonize the proinflammatory interactions of pneumolysin with human neutrophils. Infect Immun 2004; 72:4327-9.
13. Fan YY, McMurray DC, Chapkin RS. Dietary (n-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. J Nutr 2003; 133:1913-20.
14. Waheed AA, Shimada Y, Heijnen HF et al. Selective binding of perfringolysin O derivative to cholesterol-rich membrane microdomains (rafts). Proc Natl Acad Sci USA 2001; 98:4926-31.
15. Nagahama MS, Hayashi S, Morimitsu S, Sakurai J. Biological activities and pore formation of Clostridium perfringens beta toxin in HL6O cells. J Biol Chem 2003; 278:36934-41.
16. Solovyova AS, Nöllman M, Mitchell TJ, Byron O. The solution structure and oligomerization behavior of two bacterial toxins, pneumolysin and perfringolysin O. Biophys J 2004; 87:540-52.
17. Saunders FK, Mitchell TJ, Walker JA, Andrew PW, Boulnois GJ. Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity. Infect Immun 1989; 57:2547-52.
18. Spreer A, Kerstan H, Bottcher T et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003; 47:2649-54.
19. Freitag NE, Jacobs KE. Examination of Listeria monocytogenes intracellular gene expression by using green fluorescent protein of Aequorea victoria. Infect Immun 1999; 67:1844-52.
20. Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 1996; 173:33-8.
21. 10 occurs via an iron-mediated mechanism in the absence of IκB degradation. Toxicol Appl Pharmacol 2000; 166:101-10.
22. Irani K, Xia Y, Zweier JL et al. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science 1997; 275:1649-52.
23. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leuk Biol 2002; 72:847-55.
24. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100:1966-71.
25. 2+ response amplitude and duration. Nature 1997; 386:855-8.
26. Vitelli MR, Filippelli A, Rinaldi B et al. Effects of docosahexaenoic acid on [Ca (2+) ] (i) increase induced by doxorubicin in ventricular rat cardiomyocytes. Life Sci 2002; 71:1905-16.
27. Honen BN, Saint DA, Laver DR. Suppression of calcium sparks in rat ventricular myocytes and inhibition of sheep cardiac RyR channels by EPA, DHA and oleic acid. J Membr Biol 2003; 196:95-103.
28. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL. Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport 2003; 14:2457-61.
29. 2+ pump of the plasma membrane. J Biol Chem 1992; 267:2115-8.
30. 2+ current in guinea pig tracheal smooth muscle cells. Eur J Pharmacol 1998; 355:257-66.
31. Hirafuji M, Ebihara T, Kawahara F, Hamaue N, Endo T, Minami M. Inhibition by docosahexaenoic acid of receptor-mediated Ca (2+) influx in rat vascular smooth muscle cells stimulated with 5-hydroxytryptamine. Eur J Pharmacol 2001; 427:195-201.
32. Rinaldi B, Di Pierro P, Vitelli MR et al. Effects of docosahexaenoic acid on calcium pathway in adult cardiomyocytes. Life Sci 2002; 71:993-1004.
33. 2+ current in adult cardiac myocytes. Cardiovasc Res 2002; 54:601-10.
34. Denys A, Aires V, Hichami A, Khan NA. Thapsigargin-stimulated MAP kinase phosphorylation via CRAC channels and PLD activation: inhibitory activation of docosahexaenoic acid. FEBS Lett 2004; 564:177-82.
35. 2+ exchange currents in HEK2931 cells. Biochem Biophys Res Comm 2004; 321:116-23.
36. 2+ mobilization and superoxide production by long- and very-long chain fatty acids. Biochem J 1995; 311:689-97.
37. Komatsu W, Ishihara K, Murata M, Saito H, Shinohara K. Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. Free Radic Biol Med 2003; 34:1006-16.
38. Lee JY, Ye J, Gao Z et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278:37041-51.
39. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD (P) H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol 2004; 173:3589-93.
40. Freedman SD, Blanco PG, Zaman MM et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560-9.
41. Freedman SD, Weinstein D, Blanco PG et al. Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol 2002; 92:2169-76.
42. Paton JC, Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity and migration by pneumolysin. Infect Immun 1983; 41:212-6.
43. Rijneveld AW, van den Dobbelsteen GP, Florquin S et al. Roles of interleukin-6 and macrophage inflammatory protein-2 in pneumolysin-induced lung inflammation in mice. J Infect Dis 2002; 185:123-6.
44. Rogers PD, Thornton J, Barker KS et al. Pneumolysin-dependent and -independent gene expression identified by cDNA microarray analysis of THP-1 human mononuclear cells stimulated by Streptococcus pneumoniae. Infect Immun 2003; 71:2087-94.
45. Maus UA, Srivastava M, Paton JC et al. Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. J Immunol 2004; 173:1307-12.
46. Hirst RA, Kadioglu A, O'Callaghan CO, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004; 138:195-201.